What you don't seem to grasp is that sub-cu is not relevant in the US, while it is popular in the EU. So omontys needs market it there, which is a smaller market with a lower profit margin.
Amgen's anemia franchise will most likely get a boost on Monday after the recall of Affymax's Omontys:
The original article is misleading. Sensipar is not a dialysis or anemia drug, it treats hyperparathyroidism (elevated level of parathyroid hormone secretion) and hypercalcemia (too much calcium in the blood). These conditions are most commonly a result of the factors that cause severe kidney damage or are side effects of dialysis. Sensipar is administered only when hyperparathyroidism or hypercalcemia is diagnosed, not as a preventive measure. Other treatment options include surgical removal of the parathyroid gland; which is much more expensive than taking Sensipar for 2 years. It doesn't make sense for this drug to be bundled into dialysis treatment because it doesn't affect the majority of dialysis patients.
The article also inflates the likely impact of the clause. Total Sensipar sales are less than $1B per year. It is unlikely that sales would drop by more than 25% per year without the exception.
What sources do you have in Thousand Oaks? Certainly not a stockbroker, an employee or a member of the Investor Relations department. Perhaps it's Mr. Ed? Try doing some research before you make silly claims; only a moron would put in a sell order for $60 at a time when the stock is selling between $66 and $68.
THOUSAND OAKS, Calif., Aug. 22, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) will target a Prescription Drug User Fee Act (PDUFA) action date of April 26, 2012 for the supplemental Biologics License Application (sBLA) to expand the indication for XGEVA® (denosumab) to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases. Bone is one of the most common places for cancer to spread. If approved in this expanded indication, XGEVA would become the first therapy licensed to prevent or delay the spread of cancer to bone.
Interesting thought, Shade. However, Amgen's cash is tied up outside the US; AFFY is a California corp. It's not likely that AMGN will go against their stated international expansion strategy to purchase a domestic company resulting in tax penalties. Not to mention that there could be difficulties with the DOJ & FTC for potential violations of antitrust in the ESA realm.
Hello SEC - I'd like to report insider trading at Goldman Sachs.
If they indeed have knowledge of an FDA decision that is not available to the public, it is illegal for them to act on that information. I sincerely doubt that is the reason for their downgrade.
Yeah, right. $1.92 million split across 1 billion shares. I don't know about you, but .192 cents per share is not the signal Amgen should be sending out to the market. If they're going to pay a dividend, it better be significant enough to make a positive statement to Wall Street.
I can understand why you'd be skeptical of Amgen's Press Releases about Prolia. Conversely, clinicaltrials.gov has only the facts. And, as evidenced by searching for denosumab trials, there are a lot of trial results already complete and many more in progress. See for yourself at the following link: http://clinicaltrials.gov/ct2/results?term=denosumab
So which company are you a shill for... Novartis, Roche, Merck? Prolia has shown superiority over bisphosphonates in multiple trials. It's just a matter of months before Oncology approval. Then the sky's the limit!
And you're basing your predictions on what? Have you actually looked at the clinical trial results for Prolia? Have you talked to anyone who had to take Fosamax; how difficult it is to comply with the treatment protocol and how large a percentage of sufferers don't?
PMO isn't even the sweet spot for Prolia. The Oncology indications just keep expanding, not just for treating bone loss, but for preventing bone loss and bone metastases. There are 36 dmab clinical trials posted at clinicaltrials.gov. This is not a flash in the pan as you are trying to make people believe.
I think the importance of today's news is related more to the "massively parallel, next-generation sequencing technology" than to the results of the actual study. This became the opening headline for the conference. That's huge! As a bonus, there may be additional Vectibix sales due to the ability to narrowly target patients for which the medication is virtually guaranteed to be effective.
It might have something to do with the clinical trial results for a Celgene oral psoriasis medication: